Boundless Bio, Inc. (BOLD) Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Boundless Bio, Inc. NASDAQ:BOLD Healthcare · Biotechnology
Mkt Cap $56.19M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Boundless Bio's merger with Serapha Bio for potential securities-law violations and fiduciary breaches.
Boundless Bio shareholders are expected to own approximately 3.7% of the combined company upon closing, and the firm is soliciting shareholders to contact it on a contingent-fee basis.
This is law-firm marketing rather than an issuer disclosure; the same release also sweeps in investigations of OPCH, PCRX, and RXO deals.
• 20d ago AI analysis › Press Release ● Major ⚠ 5
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
Serapha Bio named Kenneth T. Mills as CEO and board member and appointed a full senior leadership team, including Daphne Karydas as President and CFO, Weston Miller as CMO, Nina Hunter as Chief Development Officer and Shiva Fritsch as Chief Corporate Affairs Officer.
The company reaffirmed that its merger with Boundless Bio (Nasdaq: BOLD) remains on track to close in Q4 2026, supported by roughly $230 million in committed pre-closing private investments co-led by RTW Investments and RA Capital, with about $138 million already funded and approximately $92 million more expected at closing. The combined company will trade on Nasdaq under the ticker AATD, subject to approval.
Lead asset SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency, has FDA IND clearance plus orphan drug and RMAT designations, with a Phase 2/3 trial slated to begin in late 2026 or early 2027 following positive investigator-initiated trial data presented at the ERS Congress.
• 1mo ago AI analysis › Press Release ● Critical ⚠ 2
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
Callio Therapeutics has appointed Zachary Hornby as Chief Executive Officer, and the release describes him in the past tense as most recently CEO, President, and a Director of Boundless Bio (Nasdaq: BOLD), the precision oncology company he led through $350 million of private and public capital raising.
For BOLD holders, the announcement functions as confirmation that the company's CEO has exited to run another biotech, and the release names no successor or transition plan at Boundless Bio.
Hornby's new company, Callio Therapeutics, is a clinical-stage developer of dual-payload antibody-drug conjugates whose lead program CLIO-8221, a HER2-targeted dual-payload ADC, entered a Phase 1/2 first-in-human trial with the first patient dosed in March 2026.
Callio co-founder Piers Ingram transitions to Senior Advisor while staying on the board and remaining CEO of Hummingbird Bioscience, which exclusively licensed the multi-payload ADC platform and pipeline to Callio in 2025.
• 1mo ago AI analysis › Press Release
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating Apogee Therapeutics regarding the proposed sale to AbbVie for $135.11 per share in cash.
The firm is examining potential violations of federal securities laws or breaches of fiduciary duties related to the transaction.
Shareholders are being encouraged to contact the law firm to discuss their rights and options regarding the deal.
• 4mo ago AI analysis › Press Release ● Critical ⚠ 3
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Boundless Bio entered into a definitive agreement to merge with privately held Serapha Bio in an all-stock transaction, pivoting away from its failed ecDNA program BBI-940 to advance Serapha's in vivo base editing therapy SERP-01 for Alpha-1 Antitrypsin Deficiency.
The transaction is backed by a $230 million concurrent private placement co-led by RA Capital and RTW Investments; BOLD stockholders will receive a special cash dividend of approximately $44 to $48 million but will retain only about 3.7% ownership of the combined company.
Post-merger, the entity will operate as Serapha Bio and trade on Nasdaq under the ticker symbol AATD, with cash runway expected to fund operations into the second half of 2029.
• 4mo ago AI analysis › Press Release ● Major
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com • 5mo ago Press Release
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
globenewswire.com • 6mo ago Press Release
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
globenewswire.com • 7mo ago Press Release
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
globenewswire.com • 7mo ago Press Release ● Critical
NurExone Announces Corporate Updates
globenewswire.com • 7mo ago Press Release
DOT'S® INTRODUCES DOT'S ORIGINAL SNACK MIX - A BOLD NEW TAKE ON SNACKING
prnewswire.com • 7mo ago Press Release ● Major
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
globenewswire.com • 7mo ago Press Release
Boundless Bio to Participate in the Leerink Global Healthcare Conference
globenewswire.com • 7mo ago 
